- Home
- BIIB vs HUBB Comparison
BIIB vs HUBB Comparison
Compare BIIB & HUBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- HUBB
- Stock Information
- Founded
- BIIB 1978
- HUBB 1888
- Country
- BIIB United States
- HUBB United States
- Employees
- BIIB N/A
- HUBB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- HUBB Industrial Machinery/Components
- Sector
- BIIB Health Care
- HUBB Technology
- Exchange
- BIIB Nasdaq
- HUBB Nasdaq
- Market Cap
- BIIB 25.1B
- HUBB 24.3B
- IPO Year
- BIIB 1991
- HUBB N/A
- Fundamental
- Price
- BIIB $160.63
- HUBB $460.09
- Analyst Decision
- BIIB Buy
- HUBB Buy
- Analyst Count
- BIIB 25
- HUBB 9
- Target Price
- BIIB $260.48
- HUBB $449.11
- AVG Volume (30 Days)
- BIIB 1.7M
- HUBB 447.4K
- Earning Date
- BIIB 10-30-2024
- HUBB 10-29-2024
- Dividend Yield
- BIIB N/A
- HUBB 1.15%
- EPS Growth
- BIIB 10.05
- HUBB 8.35
- EPS
- BIIB 11.06
- HUBB 13.89
- Revenue
- BIIB $9,607,500,000.00
- HUBB $5,640,000,000.00
- Revenue This Year
- BIIB N/A
- HUBB $8.17
- Revenue Next Year
- BIIB N/A
- HUBB $5.08
- P/E Ratio
- BIIB $14.52
- HUBB $33.12
- Revenue Growth
- BIIB N/A
- HUBB 7.50
- 52 Week Low
- BIIB $153.62
- HUBB $295.90
- 52 Week High
- BIIB $268.30
- HUBB $481.35
- Technical
- Relative Strength Index (RSI)
- BIIB 33.97
- HUBB 56.46
- Support Level
- BIIB $156.09
- HUBB $451.78
- Resistance Level
- BIIB $160.63
- HUBB $465.79
- Average True Range (ATR)
- BIIB 3.99
- HUBB 11.02
- MACD
- BIIB 0.46
- HUBB 0.39
- Stochastic Oscillator
- BIIB 31.52
- HUBB 64.36
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About HUBB Hubbell Inc
Hubbell is a diversified conglomerate industrial company that mostly competes in the electrical components market. Its products and services serve vital portions of the U.S. electrical supply chain, including transmission and distribution as well as the commercial, industrial, and residential end markets. The company organizes its business into two segments: Utility Solutions Segment and the Electrical Solutions Segment. It derives maximum revenue from Utility Solutions Segment.